These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10574683)

  • 1. Disposition of tiludronate (Skelid) in animals.
    Davi H; Tronquet C; Caix J; Simiand J; Briot C; Berger Y; Thiercelin JF
    Xenobiotica; 1999 Oct; 29(10):1017-31. PubMed ID: 10574683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human pharmacokinetics of tiludronate.
    Sansom LN; Necciari J; Thiercelin JF
    Bone; 1995 Nov; 17(5 Suppl):479S-483S. PubMed ID: 8573422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of bisphosphonates in rabbits.
    Luurila S; Kautiainen S; Ylitalo P; Ylitalo R
    Pharmacol Toxicol; 1999 Jan; 84(1):24-8. PubMed ID: 9974186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake.
    Lin JH; Chen IW; deLuna FA
    Drug Metab Dispos; 1994; 22(3):400-5. PubMed ID: 8070316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The disposition and metabolism of flurbiprofen in several species including man.
    Risdall PC; Adams SS; Crampton EL; Marchant B
    Xenobiotica; 1978 Nov; 8(11):691-703. PubMed ID: 103331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.
    Reginster JY
    Bone; 1992; 13(5):351-4. PubMed ID: 1419375
    [No Abstract]   [Full Text] [Related]  

  • 7. Biodistribution and plasma protein binding of zoledronic acid.
    Weiss HM; Pfaar U; Schweitzer A; Wiegand H; Skerjanec A; Schran H
    Drug Metab Dispos; 2008 Oct; 36(10):2043-9. PubMed ID: 18625688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1.
    Delguste C; Amory H; Guyonnet J; Thibaud D; Garnero P; Detilleux J; Lepage OM; Doucet M
    J Vet Pharmacol Ther; 2008 Apr; 31(2):108-16. PubMed ID: 18307502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates: a review of their pharmacokinetic properties.
    Lin JH
    Bone; 1996 Feb; 18(2):75-85. PubMed ID: 8833200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tiludronate: bone pharmacology and safety.
    Bonjour JP; Ammann P; Barbier A; Caverzasio J; Rizzoli R
    Bone; 1995 Nov; 17(5 Suppl):473S-477S. PubMed ID: 8573421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders.
    Murakami H; Takahashi N; Sasaki T; Udagawa N; Tanaka S; Nakamura I; Zhang D; Barbier A; Suda T
    Bone; 1995 Aug; 17(2):137-44. PubMed ID: 8554921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition and metabolism of benoxaprofen in laboratory animals and man.
    Chatfield DH; Green JN
    Xenobiotica; 1978 Mar; 8(3):133-44. PubMed ID: 418580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic disposition and pharmacokinetics of pelrinone, a new cardiotonic drug, in laboratory animals and man.
    Scatina JA; Hicks DR; Kraml M; Cayen MN
    Eur J Drug Metab Pharmacokinet; 1990; 15(1):37-48. PubMed ID: 2384116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
    Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
    Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals.
    Lin JH; Duggan DE; Chen IW; Ellsworth RL
    Drug Metab Dispos; 1991; 19(5):926-32. PubMed ID: 1686238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal safety of tiludronate.
    Neer RM
    Bone; 1995 Nov; 17(5 Suppl):501S-503S. PubMed ID: 8573427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density.
    Ammann P; Rizzoli R; Caverzasio J; Shigematsu T; Slosman D; Bonjour JP
    J Bone Miner Res; 1993 Dec; 8(12):1491-8. PubMed ID: 8304051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic disposition of 6-ethyl-3-(1H-tetrazol-5-yl)-chromone, a new antiallergic agent, in the rat, guinea-pig, rabbit, dog and monkey.
    Kanai Y; Nakai Y; Nakajima N; Tanayama S
    Xenobiotica; 1979 Jan; 9(1):33-50. PubMed ID: 104449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy.
    Murakami H; Nakamura T; Tsurukami H; Abe M; Barbier A; Suzuki K
    J Bone Miner Res; 1994 Sep; 9(9):1355-64. PubMed ID: 7529459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.